A Three-Gene Signature for Predicting the Prognosis of Patients Treated with Transarterial Chemoembolization (TACE) and Identification of PD-184352 as a Potential Drug to Reverse Nonresponse to TACE.
Zicong XiaWenjing ZhaoJibin LiuJing ZhangJing PanKang ChenLele WangHui ZhaoXiaoqing ChenPublished in: Journal of oncology (2022)
We constructed a TACE-specific three-gene signature that could be used to predict HCC patients' responses to and prognosis after TACE treatment. PD-184352 might have potential as a drug to improve TACE efficacy.
Keyphrases
- end stage renal disease
- copy number
- ejection fraction
- genome wide
- newly diagnosed
- chronic kidney disease
- prognostic factors
- peritoneal dialysis
- radiofrequency ablation
- wastewater treatment
- gene expression
- drug induced
- genome wide identification
- dna methylation
- adverse drug
- climate change
- combination therapy
- liver metastases
- genome wide analysis